PURPOSE: In this study, we explored the breadth of CD8 T cell reactivity to preproinsulin (PPI) in type 1 diabetes. MATERIALS AND METHODS: We tested a complete peptide set in pools covering all 406 potential 8-11mer epitopes of PPI and 61 algorithm-predicted human leukocyte antigen (HLA)-A2-specific epitopes (15 pools) from islet-specific glucose-6-phophatase catalytic subunit-related protein (IGRP), using a CD8-specific granzyme B enzyme-linked immunosorbent spot assay. RESULTS: Responses were seen to 64 of the 102 PPI pools in two or more newly diagnosed patients (63%) compared to 11 pools in the control subjects (11%, p < 0.0001, Fisher's exact test). We identified five pools containing 20 peptides, which distinguished patients from control subjects, most of which had predicted low-affinity binding to HLA class I molecules. In contrast, fewer (5 of 15 = 33%) IGRP peptide pools, selected by higher binding affinity for HLA-A2 (present in seven of eight patients and five of seven control subjects), stimulated responses in two or more patients, and none stimulated responses in more than two control subjects (p = 0.042, Fisher's exact test). CONCLUSION: Thus, we conclude that CD8 T cell reactivity to PPI in patients with type 1 diabetes can be much broader than shown previously and more diverse than seen in control subjects. Furthermore, responses were often stimulated by peptides with low predicted HLA-binding affinities.
PURPOSE: In this study, we explored the breadth of CD8 T cell reactivity to preproinsulin (PPI) in type 1 diabetes. MATERIALS AND METHODS: We tested a complete peptide set in pools covering all 406 potential 8-11mer epitopes of PPI and 61 algorithm-predicted human leukocyte antigen (HLA)-A2-specific epitopes (15 pools) from islet-specific glucose-6-phophatase catalytic subunit-related protein (IGRP), using a CD8-specific granzyme B enzyme-linked immunosorbent spot assay. RESULTS: Responses were seen to 64 of the 102 PPI pools in two or more newly diagnosed patients (63%) compared to 11 pools in the control subjects (11%, p < 0.0001, Fisher's exact test). We identified five pools containing 20 peptides, which distinguished patients from control subjects, most of which had predicted low-affinity binding to HLA class I molecules. In contrast, fewer (5 of 15 = 33%) IGRP peptide pools, selected by higher binding affinity for HLA-A2 (present in seven of eight patients and five of seven control subjects), stimulated responses in two or more patients, and none stimulated responses in more than two control subjects (p = 0.042, Fisher's exact test). CONCLUSION: Thus, we conclude that CD8 T cell reactivity to PPI in patients with type 1 diabetes can be much broader than shown previously and more diverse than seen in control subjects. Furthermore, responses were often stimulated by peptides with low predicted HLA-binding affinities.
Authors: Gabrielle G M Pinkse; Odette H M Tysma; Cees A M Bergen; Michel G D Kester; Ferry Ossendorp; Peter A van Veelen; Bart Keymeulen; Danny Pipeleers; Jan W Drijfhout; Bart O Roep Journal: Proc Natl Acad Sci U S A Date: 2005-12-09 Impact factor: 11.205
Authors: D L Kaufman; M Clare-Salzler; J Tian; T Forsthuber; G S Ting; P Robinson; M A Atkinson; E E Sercarz; A J Tobin; P V Lehmann Journal: Nature Date: 1993-11-04 Impact factor: 49.962
Authors: Patrick A Ott; Marcus T Dittrich; Bernhard A Herzog; Robert Guerkov; Peter A Gottlieb; Amy L Putnam; Ivana Durinovic-Bello; Bernhard O Boehm; Magdalena Tary-Lehmann; Paul V Lehmann Journal: J Clin Immunol Date: 2004-07 Impact factor: 8.317
Authors: Sigal Fishman; Mark D Lewis; L Khai Siew; Evy De Leenheer; Dimitri Kakabadse; Joanne Davies; Doron Ziv; Alon Margalit; Nathan Karin; Gideon Gross; F Susan Wong Journal: Mol Ther Date: 2017-01-18 Impact factor: 11.454
Authors: Benjamin G Vincent; Ellen F Young; Adam S Buntzman; Rosemary Stevens; Thomas B Kepler; Roland M Tisch; Jeffrey A Frelinger; Paul R Hess Journal: J Immunol Date: 2010-03-10 Impact factor: 5.422
Authors: Tarvo Rajasalu; Helen Brosi; Cornelia Schuster; Andreas Spyrantis; Bernhard Otto Boehm; Lieping Chen; Jörg Reimann; Reinhold Schirmbeck Journal: Diabetes Date: 2010-05-18 Impact factor: 9.461
Authors: Andreas Bonertz; Jürgen Weitz; Dong-Ho Kim Pietsch; Nuh N Rahbari; Christoph Schlude; Yingzi Ge; Simone Juenger; Israel Vlodavsky; Khashayarsha Khazaie; Dirk Jaeger; Christoph Reissfelder; Dalibor Antolovic; Maximilian Aigner; Moritz Koch; Philipp Beckhove Journal: J Clin Invest Date: 2009-10-05 Impact factor: 14.808
Authors: J R F Abreu; S Martina; A A Verrijn Stuart; Y E Fillié; K L M C Franken; J W Drijfhout; B O Roep Journal: Clin Exp Immunol Date: 2012-10 Impact factor: 4.330
Authors: F Susan Wong; Lai Khai Siew; Gwen Scott; Ian J Thomas; Stephen Chapman; Christophe Viret; Li Wen Journal: Diabetes Date: 2009-02-10 Impact factor: 9.461